GlaxoSmithKline Agrees to Pay $3 Billion in U.S. Drug Settlement
GlaxoSmithKline Plc (GSK) agreed to plead guilty and pay a $3 billion settlement to resolve criminal and civil charges linked to the company’s illegal promotion of prescription drugs and its failure to report safety data, according to a U.S. Justice Department statement today.
The agreement is the largest health-care fraud settlement in the U.S. and the largest payment by a drug company, the department said in the statement.
To contact the reporter on this story: Seth Stern in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Justin Blum at email@example.com